Global Scientific Conference invites participants from all over the world to attend Global Congress on Vaccines & Vaccination during March 07-08, 2017 in Dubai which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.
Vaccines 2018 Conference is brings together researchers, public health professionals and other key stakeholders to discuss progress and challenges in Vaccines research and development and implementation as identified in the universal Vaccines accomplishment. This event gives a chance for academic and health professionals to gain and share information on Vaccines research and development. We do expect this conference will be an opportunity to meet and gather with colleagues from different countries and other parts of Dubai.
Track 1: Vaccines against Infectious diseases
New Vaccine techniques like in vitro gene-manipulation have opened up new approaches to vaccine development. This has rapidly grown into an exciting area of Vaccines against infectious diseases research in both academic and industrial laboratories. There are a number of scientific challenges which require multidisciplinary teams to solve problems in developing new immunogens. This has challenged our existing knowledge about protein structure and conformation, microbial pathogenicity and the immune system. Recombinant-DNA techniques are invaluable as tools of analysis and antigen production. The surface of micro-organisms can also be minutely explored with the use of synthetic peptides and monoclonal antibodies. Nevertheless, these new technologies do not allow us to circumvent the need for detailed understanding of pathogens and the disease process. A lot of researches are going on to improve/develope new vaccines and administration of vaccines
Track 2: Cancer Vaccines
Mainly Cancer vaccines are two types preventive and therapeutic. Cancer preventive vaccines target infectious agents that cause or contribute to the development of cancer. They are similar to traditional vaccines, which help prevent infectious diseases. Polio Vaccines by protecting the body against polio. Both cancer preventive vaccines and traditional vaccines are based on antigens that are carried by infectious agents and that are relatively easy for the immune system to recognize as foreign.
Track 3: Hepatitis Vaccines
Viruses that primarily attack the liver are called hepatitis viruses. There are several types of hepatitis viruses including types A, B, C, D, E, and possibly G. Types A, B, and C are the most mundane. Viral Hepatitis B virus infection and C can cause chronic hepatitis. Vaccination for hepatitis makes the immune system to protect from hepatitis viruses.
Track 4: Bacterial Vaccines
Vaccine for antigenic substance prepared from the causative agent of a disease or a synthetic substitute, used to provide immunity against one or several diseases. Vaccination is one of the greatest breakthroughs in modern medicine. No other medical intervention has done more to save lives and improve quality of life. Bacterial vaccines contain killed or attenuated bacteria that activate the immune response. Antibodies are built against that particular bacteria, and prevents bacterial infection later. An example of bacterial vaccines is the tuberculosis vaccines
Track 5: DNA Vaccines
Genetic/ DNA immunization is a novel technique used to efficiently stimulate humoral and cellular immune response to protein antigens. The direct injection of genetic material into a living host causes a small amount of its cells to produce the introduced gene products. This inappropriate gene expression within the host has important Immunological Abnormalities, resulting in the specific immune activation of the host against the gene delivered antigen
Track 6: Combination Vaccines
The Number of Immunizations recommended is dramatically increasing day by day, especially for Childhood Vaccines United States the recommended immunization schedules for 2010 indicate that in the first 2 years children are expected to receive vaccines against 14 diseases. These combination Vaccine Adjuvants will deliver multiple vaccines in single visit/administration. Some of the combination vaccines are DTaP (DT) Vaccines, Tdap Vaccines etc.
Track 7: Edible vaccines
Edible vaccines and Recombinant Vector Vaccines mostly useful as these are easy-to-administer, cost-effective, Less Storage problems, and easily acceptable vaccine delivery system, especially for the poor or developing countries. It involves introduction of selected desired genes into plants and then inducing these altered plants to manufacture the encoded proteins. Introduced as a concept about a decade ago, it has become a reality today. A variety of delivery systems have been developed. Initially thought to be useful only for preventing infectious diseases, it has also found application in prevention of Autoimmunity related diseases, birth control, cancer therapy, etc.
Track 8: Viral vaccines
Viral vaccines contain either inactivated viruses or attenuated (alive but not capable of causing disease) viruses. Inactivated or killed viral vaccines contain viruses, which have lost their ability to replicate and in order for it to bring about a response it contains more antigen than live vaccines. Attenuated vaccines or live vaccines contain the live form of the virus. These viruses are not pathogenic but are able to induce an immune response.
Track 9: Vaccines against Vector borne Diseases
Mosquitoes, blackflies, sandflies, ticks, and lice are effective vectors of disease, transmitting pathogens via their blood meals. These Neglected Tropical Diseases (NTDs), are mostly diseases of poverty, and responsible for major economic burdens through disability, death of principal earners and missed educational opportunities for children and young adults, helping to maintain the poverty trap. It is no coincidence that the countries most affected by these diseases are also amongst the poorest countries in the world. Malaria is the most serious and costly of the insect-borne diseases with over 200 million cases of people being sick, and currently causing about 660,00 deaths per year, mostly children under the age of 5. The tragedy is that all these deaths could be stopped with a determined and coordinated approach.
Track 10: Travel Vaccines
The measles-mumps-rubella (MMR) vaccine is very important for travelers. Each year, unvaccinated people get measles while in other countries and bring it to the United States. This has sometimes led to outbreaks. Since 2000, when measles was declared eliminated from the U.S., the annual number of people reported to have measles ranged from a low of 37 people in 2004 to a high of 668 people in 2014. The majority of measles cases brought into the U.S. come from U.S. residents. When we can identify vaccine status, almost all are unvaccinated. However, it may not just be MMR vaccine that you need. You may be exposed to different diseases based on the countries you are visiting. For example, you may need the yellow fever vaccine if traveling to certain countries in Africa or Central or South America. If traveling to Asia, Latin America, or Africa, you may need typhoid vaccine.
Track 11: Mosquito-borne Diseases-Vaccines
Mosquito borne infectious diseases are among important group of diseases worldwide. Vaccination is available for some tropical mosquito-borne diseases, especially for Japanese encephalitis virus infection and yellow fever. There are also several attempts to develop new vaccines for the other mosquito-borne diseases such as malaria, dengue infection and West Nile virus infection.
Track 12: Protein Based Vaccines
Protein based subunit vaccines present an antigen to the immune system without viral particles, using a specific, isolated protein of the pathogen. A weakness of this technique is that isolated proteins, if denatured, may bind to different antibodies than the protein of the pathogen. Commonly used protein-based subunit vaccines.
Track 13: Toxoid Vaccines
Toxoid vaccines are made from a toxin (poison) that has been made harmless but that elicits an immune response against the toxin. are based on the toxin produced by certain bacteria (e.g. tetanus or diphtheria). The toxin invades the bloodstream and is largely responsible for the symptoms of the disease. The protein-based toxin is rendered harmless and used as the antigen in the vaccine to elicit immunity. Many companies’ immunoinformatics help full in this regard to increase the immune response what are the best measures, the toxoid is adsorbed to aluminium or calcium salts, which serve as adjuvants.
Track 14: Geriatric Immunization
Older adults are at increased risk for many vaccine-preventable diseases. Auto immunity is at low levels for older adults. Preventable illnesses cause substantial morbidity and mortality in older patients, who tend to have more medical co-morbidities and are at higher risk for complications. Acute respiratory infections, including pneumonia and influenza, are the 8th leading cause of death in the United States, accounting for 56,000 deaths annually. On average, influenza leads to more than 200,000 hospitalizations and 36,000 deaths each year (DHHS, Healthy People 2020).’
Track 15: Immune mediated Diseases-Vaccines
Patients with immune-mediated inflammatory diseases (IMID) such as RA, IBD or psoriasis, are at increased risk of infection, partially because of the disease itself, but mostly because of treatment with immunomodulatory or immunosuppressive drugs. In spite of their elevated risk for vaccine-preventable disease, vaccination coverage in IMID patients is surprisingly low. This review summarizes current literature data on vaccine safety and efficacy in IMID patients treated with immunosuppressive drugs or immunomodulatory drugs and formulates best-practice recommendations on vaccination in this population. Especially in the current era of biological therapies, including TNF-blocking agents, special consideration should be given to vaccination strategies in IMID patients. Clinical evidence indicates that immunization of IMID patients does not increase clinical or laboratory parameters of disease activity. Live vaccines are contraindicated in immunocompromized individuals, but non-live vaccines can safely be given. Although the reduced quality of the immune response in patients under immunotherapy may have a negative impact on vaccination efficacy in this population, adequate humoral response to vaccination in IMID patients has been demonstrated for hepatitis B, influenza and pneumococcal vaccination. Vaccination status is best checked and updated before the start of immunomodulatory therapy: live vaccines are not contraindicated at that time and inactivated vaccines elicit an optimal immune response in immunocompetent individuals.
Track 16: Innovative Development of Vaccines
New technological advances have accelerated vaccine research and development (R&D) yielding numerous vaccines that have significantly reduced mortality and morbidity. In fact, each year, vaccines prevent up to 2.5 million child deaths. But a number of diseases still lack an effective means of prevention; some, like HIV and AIDS, are caused by complex viruses that despite significant progress to-date, have proven to be evasive of existing vaccine technologies. With the emergence and expansion of new diseases, the need and demand for innovative vaccines continues to grow. But vaccine development is a complex, arduous, and expensive process. It requires a mastery of multiple technologies, ample funds for clinical trials and manufacturing facilities, sophisticated scale-up processes, expertise in navigating demanding regulatory environments in various regions, and managing vigorous safety monitoring. The R&D-based vaccine industry’s knowledge and capacity make it well-positioned to develop and manufacture new vaccine candidates. While both public and private partners play vital roles in vaccine development, it is industry that generally drives and manages the overall process that results in the approval of a new Vaccine.
Track 17: Mucosal vaccines
Mucosal surfaces are enormous surface areas that are vulnerable to infection by pathogenic microorganisms. The adaptive immune system is designed to distinguish antigens, pathogens and vaccines that enter the body through mucosal surfaces from those that are introduced directly into tissues or the bloodstream by injection or injury. It is becoming increasingly clear that local mucosal immune responses are important for protection against disease: for example, autoimmunity of mucosal antibodies against Vibrio cholera bacteria and cholera toxin are associated with resistance to cholera, department cellular immunology is very helpful in mucosal vaccines formulation.
Track 18: Child hood and maternal vaccines
Auto immunity and Vaccines help make you immune to serious diseases without getting sick first. Without a vaccine, you must actually get a disease in order to become immune to the germ that causes it. Vaccines work best when they are given at certain ages. For example, children don’t receive measles vaccine until they are at least one year old. If it is given earlier it might not work as well. The Centers for Disease Control and Prevention publishes a schedule for childhood vaccines, Adjuvants in Immunology is also plays an important role in vaccines formulation.
Track 19: Vaccines for unconventional diseases
When vaccines are mentioned most people think of immunization. Autoimmunity against childhood infectious diseases. However, in recent years the uses to which vaccines are being put has dramatically expanded beyond traditional infectious disease applications. Vaccines currently in preclinical and clinical development target prevention or treatment of a wide range of non-infectious diseases including cancer, allergy, asthma, diabetes, rheumatoid arthritis, lupus, hypertension, heart disease, obesity, Alzheimer’s disease, Parkison’s disease and even nicotine and cocaine addiction. For the most part such vaccines aim to induce neutralizing antibodies against foreign or self-antigens, thereby blocking their activity and ability to induce disease. This commentary reviews key clinical advances in the area of unconventional vaccines and identifies some of the key challenges that need to be overcome in order for unconventional vaccines and Immunomodulation research to move forward to medical and commercial success.
Track 20: Developing Conjugate Vaccines
A conjugate vaccine is created by covalently attaching a poor (polysaccharide) antigen to a carrier protein (preferably from the same microorganism), thereby conferring the immunological attributes/ Immunological Tolerance of the carrier to the attached antigen.
Track 21: Plant Derived Vaccines
Plants offer enormous potential as production platforms for vaccines and therapeutic proteins. Plant-derived vaccines, for example, present an alternative to conventional vaccines by facilitating safe and effective oral delivery through consumption of edible plant tissue. Many infectious diseases enter the body through mucosal surfaces such as the gut, and as a result, vaccines expressed in the form of edible plant tissues offer a select advantage. The plant tissues can protect the antigen as it passes through the digestive tract. Plants are capable of producing recombinant antigens that undergo similar post-translational modifications as their mammalian-derived counterparts and in contrast to bacterial expression systems. Moreover, high yields of biopharmaceuticals can be obtained, depending on the specific plant production platform. After these purification steps, the cost of producing plant-derived proteins represents only a fraction of the cost of proteins produced from analogous mammalian cell culture systems.
Track 22: Vaccines for Pregnant women and Neonates
There is a special CDC guidelines for the vaccines you need before, during, and after pregnancy. Some vaccines, such as the measles, mumps, rubella (MMR Vaccines) vaccine, should be given a month or more before pregnancy. You should get some vaccines, like Tdap (to protect against whooping cough), during pregnancy. Other vaccines, like the flu shot, can be given before or during pregnancy, depending on whether pregnant. It is safe for a woman to receive Human papilloma vaccines right after giving birth, even while she is breastfeeding. Be sure to discuss each vaccine with your health care professional before getting vaccinated.
Track 23: Animal Immunization
The major goals of veterinary vaccines and Preclinical Vaccine Studies are to improve the health and welfare of companion animals, increase production of livestock in a cost-effective manner, and prevent animal-to-human transmission from both domestic animals and wildlife. These diverse aims have led to different approaches to the development of veterinary vaccines from crude but effective whole-pathogen preparations to molecularly defined subunit vaccines, genetically engineered organisms or chimeras, vectored antigen formulations, and naked DNA injections. The final successful outcome of vaccine research and development is the generation of a product that will be available in the marketplace or that will be used in the field to achieve desired outcomes.
Track 24: Vaccines Adjuvants
The goal of vaccination is the generation of a strong immune response to the administered antigen able to provide long-term protection against infection. To achieve this objective with killed as opposed to live attenuated vaccines, often requires the addition of an adjuvant. Adjuvants are compounds that enhance the specific immune response against co-inoculated antigens.
Track 25: Vaccines Industry
The renaissance in the vaccine market continues with strong growth and new prospects to continue to grow this part of the market, which now stands at about $25 billion. Immunological Research Once a commodity market with low margins, the vaccines on the market now include blockbusters and mega blockbusters. New candidates for vaccinating against cancers and HIV Vaccines Research & Development are also projected to hit the magic milestone. The market is expected to return a compound annual growth rate of more than 8percent through 2018, Evaluate Pharma projects, with some segments like adult vaccines showing even better.
Track 26: Vaccines Trials
Delivery of a vaccine in a programme such as Expanded Program on Immunization is the end result of years of discovery and development. Only a tiny percentage of candidate vaccines progress to licensing, making the costs of vaccine Research and Development extremely high. This fact also makes it essential to maintain a healthy product portfolio, with a range of vaccines at different stages in the pipeline.
Development of vaccines can be simplified into two broad stages:
Pre-clinical vaccines studies development is research carried out in lab assays and on animals. It includes: Immuno Thereapeutics Clinical development is when the vaccine is first tested in humans. It covers four stages over several years, from initial clinical trials in humans (phase I) right through to introduction and beyond (phase IV). Clinical development is built on rigorous ethical principles of informed consent from volunteers, with an emphasis on vaccine safety as well as efficacy.
Phase I clinical trials are small-scale trials to assess whether the vaccine is safe in humans and what immune response it evokes. For diseases of poverty this covers trials in European volunteers (phase Ia) and then in populations in Developing Countries (phase Ib).
Phase II clinical trials are larger and look mainly to assess the efficacy of the vaccine against artificial infection and clinical disease. Vaccine safety, side-effects and the immune response are also studied.
Vaccines that progress to phase III clinical trials are studied on a large scale of many hundreds of subjects across several sites to evaluate efficacy under natural disease conditions. If the vaccine retains safety and efficacy over a defined period, the manufacturer is able to apply to the regulatory authorities for a licence to market the product for human use.
The final phase IV happens after the vaccine has been licensed and introduced into use. Also called post-marketing surveillance, this stage aims to detect rare adverse effects as well as to assess long term efficacy.
Track 27: Vaccines Delivery Techniques
Currently excruciating research activity aimed at the development of incipient distribution systems for vaccines. The goal is to identify optimal methods for presenting target antigens to the Adaptive immunity in a manner that will elicit immune replications congruous for aegis against, or treatment of, a categorical disease. Several different approaches to this general goal have been developed, some are empirical and remain poorly understood, and others are more rational, being predicated, for example, on mimicking natural infections in vivo or on targeting particular features of the immune system. This article will review three categories of distribution systems: adjuvants and formulations; antigen vectors, including live attenuated micro-organisms and synthetic vectors; and novel contrivances for vaccine administration.
Track 28: Formulation
The renaissance in the vaccine market continues with strong growth and new prospects to continue to grow this part of the market, which now stands at about $25 billion. Once a commodity market with low margins, the vaccines on the market now include blockbusters and mega blockbusters. New candidates for vaccinating against cancers and HIV are also projected to hit the magic milestone. The market is expected to return a compound annual growth rate of more than 8percent through 2018, Evaluate Pharma projects, with some segments like adult vaccines showing even better.
Track 29: Vaccines Business Development
Vaccines Business development: comprise a number of tasks and processes generally aiming at developing and implementing growth opportunities within and between organizations. It is a subset of the fields of business, commerce and organizational theory.